Virus-driven cancers such as MCC offer ideal model systems in which to track and assess cancer-specific T and B cell responses throughout treatment with PD-1 axis blockade as the majority of MCCs are driven by key portions of MCPyV oncoproteins. This evidence concerns the gene PDCD1 and cancer.